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Abstract Hypertension secondary to chronic kidney disease
prevails in earlier childhood and obesity-related primary hyper-
tension in adolescence. Both are associated with a high risk of
renal and cardiovascular morbidity. In children with chronic
kidney disease, uncontrolled hypertension may accelerate pro-
gression to end-stage renal disease before adulthood is reached
and increase a child’s risk of cardiac death a thousand-fold.
Obesity-related hypertension is a slow and silent killer, and
though early markers of renal damage are recognized during
childhood, end-stage renal disease is a risk in later life. Renal
damage will be a formidable multiplier of cardiovascular risk for
adults in whom obesity and hypertension tracks from childhood.
Management options to prevent renal damage will vary for these
different target groups. This review provides a summary of the
available renoprotective strategies in order to aid physicians
involved in the care of this challenging group of children.
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Introduction
Kidney damage is the second-most common complication of
primary hypertension after cardiovascular events, and significant-
ly contributes to the increasing number of adults with end-stage
renal disease (ESRD) [1]. In patients with established chronic
kidney disease (CKD), hypertension is one of themost important
predictors of further disease progression. In both primary and
secondary hypertension, renal damage represents a formidable
multiplier of the patient’s global cardiovascular (CV) risk [2].
Evidence for the above statements derives from both experimen-
tal studies and a multitude of clinical studies on end-organ
damage in the adult hypertensive population for whom primary
hypertension is amajor issue and diabetes amajor cause of CKD.
Most of the existing strategies to prevent renal damage and
cardiovascular events in primary hypertension and CKD patients
are also based on studies from adult populations. In childhood,
the causes and epidemiology of both hypertension and chronic
kidney disease differ from those observed in later life.
In younger children, hypertension secondary to renal disease
prevails, with primary hypertension becoming a major issue in
adolescence [3, 4••, 5]. The main contributor to childhood CKD
is congenital abnormalities of the kidney and urinary tract
(CAKUT), whereas diabetic nephropathy is a marginal cause.
While the prevalence of hypertension in children and adolescents
has doubled in the last two decades, it is still much lower than
that observed in adults [4••]. Studies performed in the childhood
hypertensive population, therefore, are scarce and frequently
require a multicenter, multinational effort to reach statistically
significant numbers. Cardiovascular morbidity and mortality, an
important primary outcome of adult hypertensive studies, are rare
events in childhood. Nevertheless, knowledge has accumulated
on both the pathophysiology of hypertension-induced kidney
damage in children and the treatment strategies used to prevent
it. Implementation of these strategies by physicians involved in
the care of the reported 4 % hypertensive children and adoles-
cents is crucial for adequate management.
Target Groups for Renoprotective Strategies in Childhood
Hypertension
A large proportion of children with hypertension have chronic
kidney disease secondary to a multitude of different renal
disorders. CAKUT constitute a major group within these,
and renal hypodysplasia is the most common diagnosis. The
prevalence of hypertension is notably high in hereditary glo-
merular, microangiopathic or cystic diseases (congenital ne-
phrotic syndrome, Alport syndrome, atypical hemolytic-
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uremic syndrome, ARPKD, ADPKD) [6, 7]. Severe hy-
pertension is also seen in acquired primary and second-
ary glomerulopathies (FSGS, extracapillary glomerulone-
phritis, lupus nephritis), or following severe acute kid-
ney injury (hemolytic–uremic syndrome, cortical necro-
sis) [8, 9].
The aim of treatment in children with established chronic
kidney disease is prevention of additional renal damage
exerted by hypertension. The goal is to slow disease progres-
sion and delay the start of renal replacement therapy (RRT). A
further, equally important aim is to decrease the well-
documented burden of cardiovascular risk associated with
declining renal function. Many adults actually die from CV
complications before reaching ESRD [10]. Though childhood
death is a rare event in CKD, cardiac death rate is a thousand-
fold higher than that of the age-matched general population
and the major cause of mortality in children on dialysis
[11–13].
The last decade has witnessed an emerging shift in the
epidemiology of childhood hypertension, parallel to the epi-
demic of childhood obesity. Primary hypertension has been
increasingly recognized in the primary care setting and has
become the leading cause of hypertension in adolescents [4••].
Similarly to patients with primary hypertension, obese chil-
dren with hypertension initially have intact kidneys.
Renoprotective strategies for this target group are aimed at
conserving normal renal function.
Renal Damage and Preventive Strategies in Hypertensive
Children with CKD
CKD Progression
In children with CKD, once significant renal damage
has occurred, progressive impairment of renal function
ensues. The rate of deterioration is partially dependent
upon the underlying renal disease, and children with
renal hypodysplasia demonstrate a much slower progres-
sion than those with glomerulonephritis [14]. Among
the modifiable factors influencing deterioration of renal
function, hypertension and proteinuria have been identi-
fied as key players. Both are independent predictors of
disease progression [15, 16]. Additional factors include
renal anemia, hyperparathyroidism, dyslipidemia, chron-
ic inflammation, oxidative stress, and genetic back-
ground [17]. In children, the decline in renal function
is frequently not linear, and an important decrease can
be noted around puberty. Data from 1,200 children
with different causes of renal disease enrolled in the
Italian CKD Registry (ItalKid) has shown that the risk
of reaching ESRD by the age of 20 is 68 % [18].
Pathophysiology of Hypertension in CKD
Hypertension is highly prevalent in children with CKD, with
rates ranging from 20 % to 80 %, depending upon the under-
lying disease and stage of renal dysfunction. The crucial
pathophysiological pathways of hypertension in CKD are
shown in Fig. 1. Activation of the renin-angiotensin-
aldosterone system (RAAS) and fluid overload are looked
upon as pivotal in the development of hypertension in CKD
subjects. Angiotensin II-mediated vasoconstriction and
aldosterone-mediated salt retention lead to increase in periph-
eral resistance and blood volume. Impaired sodium excretion
leading to expansion of extracellular fluid volume and periph-
eral vasoconstriction is frequent in later stages of CKD [19].
Other important factors contributing to CKD hypertension are
sympathetic hyperactivation, chronic hyperparathyroidism,
endothelial dysfunction, reduced renalase activity, drug ad-
ministration (cyclosporine, glucocorticoids, EPO) and sleep
apnea [20–22].
Therapeutic Strategies to Slow Progression of Renal Damage
in CKD
The two most important strategies for slowing CKD progres-
sion that have emerged in the last years are adequate blood
pressure control and minimization of proteinuria. There is less
substantial data for the renoprotective effects of treating renal
anemia, uremic dyslipidemia, and mineral metabolism disor-
ders [23]. Therefore, the mainstay of renoprotective therapy in
CKD is effective antihypertensive treatment, which not only
attenuates worsening of renal function but also reduces pro-
teinuria, and is effective in preventing cardiovascular events,
as has been demonstrated in adults and children [12, 13, 24•].
How Low Do We Reduce Blood Pressure in Children
with CKD?
Based on initial data from large adult trials, international
guidelines unanimously recommended blood pressure values
below 130/80 mmHg (with some indicating lower values –
125/75 mmHg when proteinuria exceeded 1 g/day) [25]. The
evidence in favor of such a low blood pressure target has been
in recent dispute. Several trials have reported a paradoxical
increase in mortality (so-called J-curve phenomenon) with
lower blood pressure regimens [26]. Though this issue appears
to be restricted to older patients with severe atherosclerosis,
the results of the AASK, MDRD, and REIN-2 trials have not
established with certainty that a lower BP target is justified in
adults [27–29]. However, a recent meta-analysis did demon-
strate a benefit of more intensive blood pressure lowering
strategies on CKD progression, particularly in proteinuric
patients, which was not accompanied by a detrimental cardio-
vascular effect [30]. This was not confirmed in non-
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proteinuric patients. Therefore, the target BP in CKD adults
remains an area of controversy.
The results of the ESCAPE trial, an international random-
ized clinical study, have clearly demonstrated a beneficial
effect of intensified blood pressure control on renal function
in the child CKD population [31••]. In this study, 41.7 % of
children in the conventional blood pressure target group
(ABPM mean arterial pressure [MAP] aimed at values be-
tween 50th and 95th percentile) reached the composite end-
point of doubling serum creatinine, decline in GFR<10 ml/
min/1.73 m2, or start of RRT. In the intensified blood pressure
target group (MAP <50th percentile), only 29.9 % of patients
reached the endpoint, which corresponded to a risk reduction
of 35 %. The treatment was well tolerated. European Guide-
lines have accordingly recommended lowering BP in children
with CKD to levels below the ambulatory 75th percentile and
for patients with proteinuria below the ambulatory 50th per-
centile [32]. In children with CKD caution in intensive blood
pressure management may be necessary in individual patients
with existing severe cardiovascular damage.
Blood pressure control in CKD patients exerts an addition-
al beneficial antiproteinuric effect, as proteinuria has repeat-
edly been shown to be a strong independent predictor of renal
progression in both adults and children [33–35]. Nevertheless
nephrotic-range proteinuria was shown in a recent study of
578 children with CKD to be strongly associatedwith poor BP
control [36]. Future research should therefore focus on strat-
egies to reduce proteinuria, as this may improve BP control
and slow the progression of CKD.
Which Antihypertensive Agents are Best for Effective
Renoprotection?
The ideal antihypertensive agent for renoprotection in children
must be effective in decreasing blood pressure to target values
and must target several mechanisms that induce renal injury,
including RAAS activation. It must have a good pediatric
safety profile and pediatric labelling, and it should need little
modification with declining GFR. The various classes of
available antihypertensive drugs are comparable in their abil-
ity to lower blood pressure and prevent cardiovascular events,
but differ in their antiproteinuric and renoprotective effect
[24•, 37]. There is strong evidence to support RAAS antago-
nists, such as ACE inhibitors (ACEI) and angiotensin receptor
blockers (ARB), as first-choice drugs for both adults and
children with CKD [25, 32, 38]. The drugs within this group
block the major pathophysiological mechanism leading to
hypertension in CKD (Fig. 1). In addition to their antihyper-
tensive efficacy, they have antiproteinuric effects and an ex-
cellent safety profile. ACE inhibitors suppress the local an-
giotensin II tone, and ARB the angiotensin II action, whereby
they reduce glomerular pressure and proteinuria, and decrease
Fig. 1 Pathophysiologic pathways of hypertension in CKD
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local cytokine release and activation of inflammatory path-
ways. This results in attenuation of glomerular hypertrophy
and sclerosis, tubulointerstitial inflammation, and fibrosis.
RAAS antagonists also normalize central nervous sympathet-
ic tone and reduce oxidative stress. Randomized controlled
studies have shown both their antiproteinuric efficacy and
their renoprotective potential in adults with CKD [29].
In children, the ESCAPE trial demonstrated the antihyper-
tensive and antiproteinuric efficacy of the ACE inhibitor
ramipril in nearly 400 patients with CKD. However, the
long-term efficacy of ACEI monotherapy was limited by a
rebound of proteinuria following 24 months of treatment
despite adequate blood pressure control. This so-called escape
phenomenon may be due to compensatory up-regulation of
ACE-independent angiotensin II production [39]. Patients
with rebound proteinuria may benefit from ARB therapy or
combination therapy with other drug groups. The
renoprotective efficacy of RAAS antagonists has also been
demonstrated in studies involving pediatric patients with CKD
following hemolytic uremic syndrome and patients with
Alport syndrome, conditions in which both hypertension and
proteinuria are relatively severe [40, 41]. In contrast, no
renoprotective effect could be demonstrated following ACE
inhibition in children with hypodysplastic kidneys from the
ItalKid Study [42].
Although calcium channel blockers (CCBs) achieve ade-
quate blood pressure goals in CKD patients, the more fre-
quently used dihydropyridine agents (amlodipine, nifedipine)
have not been shown to slow progression of CKD or reduce
proteinuria. Their use is limited to combination therapy with
RAAS antagonists.
Beta-blockers are useful agents in reducing the
overactivation of the sympathetic nervous system observed
in CKD patients, resulting in reduction of cardiac output and
afterload, pulse rate, and additional renal renin release. Al-
though the renoprotective (atenolol, metoprolol) and
antiproteinuric effects (metoprolol, carvedilol) of this class
of drugs has been demonstrated, they are most commonly
used when combination therapy is necessary for adequate
blood pressure control [43–45].
Sympathetic activity has also been shown to normalize
following bilateral nephrectomy, with a concomitant reduc-
tion in blood pressure [20]. A recent report demonstrated the
beneficial effect of renal denervation therapy by high-
frequency radio-ablation in adult patients with CKD [46]. This
therapy had been previously used for the treatment of resistant
hypertension in patients with preserved renal function [47].
Combination Therapy and Dosage Regimens
Monotherapy with RAAS antagonists effectively lowers
blood pressure in a subgroup of CKD children, although
antiproteinuric effects may require higher doses than those
registered for hypertensive treatment [48]. Recommended
pediatric dosing of antihypertensive drugs and their renal
clearance are available in two recent reviews on the pharma-
cological treatment of hypertension [49, 50]. Most ARBs
(with the exception of olmesartan), CCBs, and alpha-
blockers do not require dose adjustments in CKD. ACEI
should be started with lower doses, and frequent response-
based dose titration is necessary in advanced CKD. Beta-
blockers (bisoprolol, nadolol, atenolol) that are eliminated
by renal clearance require dose adjustments, while metoprolol,
carvedilol, and labetalol do not, as they are metabolized by the
liver.
Abnormal patterns of circadian BP rhythms in the form of
nocturnal hypertension or non-dipping during sleep are com-
mon in the CKD population. This can be improved by admin-
istration of a nighttime dose of one of the prescribed antihy-
pertensive medications [51].
When highest-approved dosage is not effective for reduc-
ing blood pressure, combination therapy is introduced. In
some children, especially those with later stages of CKD,
multidrug therapy is necessary. In the ESCAPE cohort, the
intensive blood pressure group required an average 0.9±1.1
additional drugs to high-dose ramipril (6 mg/kg/m2) to
achieve target blood pressure [31••]. The most frequently used
combination therapy for CKD patients is RAAS antagonists
with a diuretic or calcium channel blocker.
The established role of the RAAS in promoting renal
damage has led researchers to test whether more profound
inhibition could be achieved through the concomitant use of
more than one RAAS antagonist. Recent clinical trials in adult
diabetic CKD patients did not confirm an additional
renoprotective benefit of combined RAAS antagonist therapy
[52–54]. The improvement in blood pressure and proteinuria
was overshadowed by greater number of side effects, mainly
hyperkalemia, emphasizing the need for a cautious and indi-
vidualized approach to such treatment in the renal patient [52].
A recent editorial on the future of double-RAAS blockade in
adults concluded that this therapy should be considered only
for those patients in whom further cardiovascular and renal
protection may be achieved without the risk of hyperkalemia
or other serious side effects [55].
Diuretics are less commonly used in early stages of CKD in
children. Those with hypodysplastic kidneys frequently dem-
onstrate polyuria and may have salt-losing nephropathy. Loop
diuretics are preferred and can be used also in later stages of
CKD, in contrast to thiazides, which are useful only in chil-
dren with GFR over 30 ml/min/1.73 m2. Spironolactone and
the newer aldosterone antagonist eplerenone carry the same
risk of hyperkalemia. Combination therapy of these agents
with ARB or ACEI, therefore, is limited in CKD patients due
to safety concerns.
Uric acid (UA) was recently implicated as a potential
modifiable factor of CKD progression. Pilot studies suggest
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that lowering UAwith allopurinol or febuxostat is associated
with significant decrease of creatinine levels [56].
Non-pharmacological Treatment for Hypertension
According to European guidelines, non-pharmacological
treatment is an essential component in the management of
every hypertensive child, including CKD subjects [32]. While
the blood pressure lowering effect of weight loss, normaliza-
tion of excessive sodium intake, and increased physical activ-
ity are probably the same for both non-CKD and CKD chil-
dren, supporting studies are lacking. The renoprotective effect
of such strategies has also not been studied. Optimal salt
intake in both the general population and CKD patients is an
area of controversy, although current recommendations of
reducing salt intake to 5–6 g/day in adults are supported by
data that higher salt intake aggravates long-term outcome [57].
Children with advanced stages of CKD and resistant hyper-
tension require salt restriction at levels similar to the pediatric
non-CKD hypertensive population. Salt restriction has been
shown to increase the antihypertensive effect of RAAS
inhibition.
A recent publication on the nutritional status of the pediat-
ric renal replacement population in Europe has shown that
both overweight (20.8 %) and obesity (12.5 %) are highly
prevalent [58]. Therapeutic intervention to address this poten-
tially modifiable cardiorenal risk factor is recommended for
the CKD child. Exercise has been shown to decrease blood
pressure in non-CKD patients. Although several studies have
looked at the beneficial effect of exercise in dialysis patients,
they did not address the influence of increased physical activ-
ity on lowering blood pressure or renal protection. Attenuation
of renal dysfunction has been shown only in experimental
animal studies [59, 60].
Sleep apnea is present in up to 30 % of the adult CKD
population, particularly in those with obesity or diabetes.
Improved ECF volume control with nocturnal HD, nocturnal
automated PD, and nasal continuous positive airway pressure
improves sleep apnea [22, 61].
Renal Damage and Preventive Strategies
in Obesity-Related Hypertension in Children
Obesity-Related Hypertension in Children
Cross-sectional studies have found that there is a significant
impact of obesity on the prevalence of childhood hyperten-
sion. A review of population studies in the United States
reveals that hypertension prevalence has nearly doubled in
recent decades, reaching 4 %. This has been attributed to the
worldwide epidemic of obesity [4••, 62]. The long-term con-
sequences of obesity are not only diabetes and cardiovascular
damage but also renal damage [63]. Recent reviews and
comments raise the concern that the ongoing obesity epidemic
will be followed by a CKD epidemic, dramatically increasing
the number of adults requiring renal replacement therapy in
the future [64].
Pathophysiology of Hypertension in Obesity
The pathophysiology of obesity-related hypertension involves
several interactingmechanisms, including sympathetic system
activation, RAAS activation, vascular endothelial dysfunc-
tion, and reduced kidney blood flow [4••, 65]. Among the
recognized initiating factors are hyperinsulinemia and insulin
resistance, disturbed adipocyte hormone production (in-
creased leptin, decreased adiponectin, increased local RAAS
components including angiotensinogen and aldosterone), di-
rect compression of the kidney by perinephric fat, production
of proinflammatory cytokines, oxidative stress, and sleep-
disordered breathing. The complex interaction of these multi-
ple mechanisms results in sodium and water retention, in-
creased peripheral resistance, and impaired vasodilatory re-
sponse, leading to increased blood pressure [66–68].
Renal Damage in Obesity-Related Hypertension
The strong relationship between obesity, metabolic syndrome,
and ESRD has become increasingly recognized [69, 70]. The
risk of renal damage observed with increasing BMI is caused
not only by hypertension and diabetes, the two most common
causes of ESRD in adults, but also by metabolic syndrome
[71]. Hyperinsulinemia and reduced insulin sensitivity seem
to play the pivotal role, acting through multiple pathways
which lead to the described obesity-related glomerulopathy
characterized by glomerulomegaly and FSGS. Renal damage
clinically presents with albuminuria/proteinuria and leads to
progressive renal dysfunction. Onset of renal injury begins in
childhood, and renal dysfunction may be recognized even
before hypertension is evident. A recent pediatric study
showed that mean estimated GFR values were significantly
lower in obese children compared to controls [72•].
Renoprotective Strategies for Children with Obesity-Related
Hypertension
Children with obesity-related hypertension require a complex
renoprotective strategy due to the multifactorial pathogenesis
of kidney damage. According to current recommendations,
obes i ty - a s soc i a t ed hype r t ens ion requ i r e s non-
pharmacological treatment including weight loss, lifestyle
modifications, and salt restriction [32, 73]. This is easier said
than done, and to be effective, will need to involve not only
the family and medical community but also the food industry
and politicians. The cornerstone of treatment is weight loss.
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Effective interventions to achieve and maintain weight reduc-
tion require a multidisciplinary approach to change family
eating behaviors and increase family and child activity [74].
Recently debated strategies include public policy interven-
tions aimed at improving nutritional quality of food, banning
the marketing of unhealthy food, taxing sweetened drinks, and
reducing the proximity of fast-food outlets to schools [75, 76].
Dietary counseling is essential, and the DASH (Dietary
Approach to Stop Hypertension) diet utilized in the United
States may also be effective for adolescents [77]. Lowering
salt intake to recommended daily values is important due to
the disturbed salt balance observed in overweight children.
The benefit of salt reduction on lowering blood pressure may
be more pronounced in the obese [78]. Dietary intervention
includes fructose restriction, which has been associated with
increased levels of uric acid, a further contributor to hyperten-
sion [79].
Current guidelines recommend 60 minutes of aerobic ac-
tivity as part of a weight management strategy [74]. Physical
activity may have benefits beyond BMI changes in hyperten-
sive children. Improved blood pressure and stabilization of
early markers of cardiovascular damage (cIMT, arterial stiff-
ness), independent of BMI changes, were demonstrated in an
exercise interventional trial in obese adolescents [80]. An
extensive review on the treatment strategies of obesity-
related hypertension was presented in an earlier issue of this
journal [81].
Pharmacological Therapy of Hypertension and Obesity
According to Endocrine Society guidelines, pharmacological
therapy for obesity is considered if intensive lifestyle modifica-
tions fail to decrease weight or improve comorbidities [74]. The
two most common agents are orlistat and metformin. Metformin
has been shown to cause a decrease in BMI and improve
markers of insulin resistance after 6 months of treatment [82].
However, the most dramatic weight reductions are reported
following bariatric surgery. The International Pediatric
Endosurgery Group (IPEG) has published recommendations
for bariatric procedures in children and adolescents [83]. Long-
term consequences of surgical treatment performed in adoles-
cence are unknown, and longitudinal studies await finalization.
To avoid nutritional deficiencies, patients must take supplements
for life [84]. Nonetheless, following bariatric surgery, the reso-
lution rates of hypertension ranged from 50–100 % [85].
Pharmacological treatment of hypertension in obese chil-
dren is indicated for severe stage 2 hypertension or in the
presence of diabetes or target-organ damage. Therapy may
also be necessary for those that do not respond to intensive
non-pharmacological management. European treatment
guidelines recommend lowering blood pressure below the
90th percentile for all hypertensive obese subjects [32]. Amer-
ican guidelines recommend a target blood pressure below the
95th percentile and lower values (<90th percentile) for those
with diabetes or target-organ damage [25].
ACE inhibitors have become the drug of choice for treating
obesity-related hypertension in adults. In addition, both
ACEIs and ARBs improve glucose tolerance, insulin levels,
and visceral fat content, and reduce the risk of type 2 diabetes
mellitus [86, 87].While there are no available pediatric studies
to support their superiority over other drug classes, ACE
inhibitors seem to be the most frequently prescribed agents
for children with hypertension [88, 89]. The rationale for their
use in hypertensive children and adolescents is that they target
the activated RAAS in patients with obesity and have an
additional renoprotective effect. Evidence from diabetic and
CKD populations supports the preferential choice of RAAS
blockade for patients with proteinuria. Although beta-blockers
target the activated sympathetic system in obese children and
diuretics increase sodium excretion, they are looked upon as
second-line agents due to their metabolic side effects. There
has been renewed interest of late in the use of aldosterone
blockade. Spironolactone and eplerenone have been shown to
be effective in drug-resistant adults [90, 91].
Antihypertensive non-pharmacological interventions and
pharmacological treatment will have a renoprotective effect
only if blood pressure targets are lowered to the levels de-
scribed above. Home and office blood pressure measurements
are necessary to document the efficacy of treatment. When
monotherapy is ineffective, additional drugs should be intro-
duced. Adherence to salt reduction and other non-
pharmacological strategies must be controlled in the case of
resistant hypertension.
Conclusion
Renal damage is a recognized complication of hypertension in
children. The two major pediatric groups at risk are those with
existing chronic renal disease and obese patients. In children
with CKD, renoprotective strategy is aimed at slowing the
decline of renal function in order to postpone renal replace-
ment therapy. The mainstay of treatment is intensive blood
pressure control and minimization of proteinuria. Mean arte-
rial blood pressure is targeted below the ambulatory 50th
percentile values and proteinuria below 300 mg/m2/day.
RAAS antagonists are the first-line treatment for both hyper-
tension and proteinuria, though many children will require
multiple-drug therapy to achieve set goals.
Renoprotection in children with obesity-related hyperten-
sion is aimed at conserving normal renal function. This can be
achieved by reversing the metabolic consequences of obesity
through weight loss. The mainstay of treatment is non-
pharmacological measures modifying lifestyle and dietary
habits, increasing physical activity, and reducing salt intake.
There is a limited role for effective pharmacological reversal
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of the metabolic consequences of obesity, and bariatric sur-
gery is controversial. Pharmacological therapy of hyperten-
sion is introduced if non-pharmacological measures fail to
lower blood pressure or if diabetes or end-organ damage is
present. First-line pharmacological antihypertensive drugs are
RAAS antagonists. A further common goal of renoprotective
strategies in children with either primary or secondary hyper-
tension is prevention of the formidable cardiovascular mor-
bidity associated with declining renal function.
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